Therini Bio
San Francisco
About Therini Bio
Therini Bio is a biotechnology company specializing in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases. It develops therapeutics based on unique insights into the novel role of fibrin in driving chronic innate immune activation that characterizes a broad set of human diseases with high unmet needs. The current therapeutic target is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $104.3M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2025)
- Website: therinibio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/therini-bio-62107 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.